C4 Therapeutics(US:CCCC) ZACKS·2025-02-27 14:20分组1 - C4 Therapeutics reported a quarterly loss of $0.49 per share, which was worse than the Zacks Consensus Estimate of a loss of $0.44, but an improvement from a loss of $0.68 per share a year ago, indicating an earnings surprise of -11.36% [1] - The company posted revenues of $5.18 million for the quarter ended December 2024, missing the Zacks Consensus Estimate by 39.45%, but showing an increase from year-ago revenues of $3.26 million [2] - C4 Therapeutics shares have declined approximately 26.4% since the beginning of the year, contrasting with the S&P 500's gain of 1.3% [3] 分组2 - The earnings outlook for C4 Therapeutics is crucial for investors, as it includes current consensus earnings expectations for upcoming quarters and any recent changes to these expectations [4] - The estimate revisions trend for C4 Therapeutics is currently favorable, resulting in a Zacks Rank 2 (Buy) for the stock, suggesting it is expected to outperform the market in the near future [6] - The current consensus EPS estimate for the upcoming quarter is -$0.42 on revenues of $4.43 million, and for the current fiscal year, it is -$1.70 on revenues of $25.44 million [7] 分组3 - The Medical - Biomedical and Genetics industry, to which C4 Therapeutics belongs, is currently ranked in the top 28% of over 250 Zacks industries, indicating a favorable outlook for stocks within this sector [8] - Another company in the same industry, Sangamo Therapeutics, is expected to report a quarterly loss of $0.09 per share, reflecting a year-over-year change of +73.5%, with revenues projected to be $15.9 million, up 679.4% from the previous year [9]